Enable job alerts via email!
A biopharmaceutical company based in Abingdon is seeking an Associate Director, Clinical Scientist to lead hematology/oncology clinical studies. The role involves study design, regulatory documentation, and managing study execution challenges. Qualified candidates will have a relevant MS or equivalent, with preference for a PhD. Excellent communication skills and expertise in immunology are essential. Join a dynamic team committed to innovative cancer therapies.
About Summit:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody that combines immunotherapy via PD-1 blockade with anti-angiogenesis effects by blocking VEGF. Ivonescimab exhibits unique cooperative binding to its targets, with higher affinity in the presence of both PD-1 and VEGF.
Summit has initiated clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:
Ivonescimab is an investigational therapy not yet approved by regulatory authorities in Summit's license territories, including the US and Europe. It was approved for marketing in China in May 2024 and has received Fast Track designation from the FDA for the HARMONi trial.
Overview of Role:
The Associate Director, Clinical Scientist, will lead and contribute to the design and execution of hematology/oncology clinical studies. This role involves collaborating with various teams to develop clinical plans, authoring regulatory documents, and ensuring high-quality data interpretation. The individual will also focus on study enrollment, building relationships with investigators and site staff, and proactively managing study execution challenges.
Responsibilities:
Qualifications: